Scientists Awarded The Albany Prize, Americas Most Distinguished Prize in Medicine, for Research Leading to Covid-19 Vaccines
September 21, 2021 - Albany, NY
Threepioneeringscientists,whosediscoveries haveled toinnovativeadvances in medicine, including the vaccines for Covid-19, were presented with the 2021 Albany Medical Center Prize in Medicine and Biomedical Research, celebrating its 20th anniversary, today during a ceremony in Albany, New York. The recipients are:
Dr. Grahams research investigated optimal immunogen structure to induce potent neutralizing responses. Dr. Karik and Dr. Weissmans research focuses on the modification of nucleic acids to develop RNA therapeutics and vaccines. As one of the breakthroughs in mRNA research their findings allowed for the rapid development of mRNA-based vaccines to address the Covid-19 pandemic.
RNA (ribonucleic acid) is a vital molecule found in human cells. Pieces of RNA are used to construct proteins inside the body so that new cells can grow. There are several different types ofRNA, including mRNA (messenger RNA), that is read by ribosomes, small protein-creating factories located inside of a human cell, to build proteins necessary for human life. mRNA is used in Covid-19 vaccines produced by Pfizer/BioNTech and Moderna. The U.S. Food and Drug Administration approved the Pfizer/BioNTech coronavirus vaccine for use in people 16 and over on August 23, 2021.
At a time when the importance of scientific achievement resounds around the world with more urgency than ever, The Albany Prize continues its long tradition of honoring the most profound and transformative discoveries in medicine and of celebrating important scientific researchers.
Since The Albany Prizes inception in 2001, the annual award of $500,000 has been granted to those who have altered and positively impacted the course of medical research. In 2020, the program paused due to the pandemic, and this year the recipients of the prize will collectively receive $1 million, double its typical amount. The Albany Prize is one of the most significant prizes in medicine and science in the United States.
I am honored and humbled to present The Albany Prize to these exceptional scientists, said Vincent P. Verdile, M.D., the Lynne and Mark Groban, M.D. 67, Distinguished Dean of Albany Medical College and Chair of The Albany Prize National Selection Committee. Collectively, The Albany Prize recipients have made major contributions to science over decades as researchers, mentors, and educators. Their years of work, scientific expertise, and sheer determination played a critical role in accelerating the development of two mRNA Covid-19 vaccines. And their dedication exemplifies The Albany Prize legacy to honor scientists whose work has demonstrated significant outcomes for the betterment of humankind.
Getting Ahead of a Pandemic
Barney S. Graham, M.D., Ph.D., an immunologist, virologist, and clinical research physician, is a pioneer in structure-based vaccine design and a thought leader on pandemic preparedness. When the genetic sequence of SARS-CoV-2 was first announced, Dr. Grahams lab, armed with years of mRNA clinical work and safety data, solved the mystery of Covid-19 with astonishing speed. Because of this success, it is expected that mRNA technology will play a vital role in the future of vaccine development.
When he began researching a concerning childhood infection, respiratory syncytial virus (RSV), nearly four decades ago, Dr. Graham, then at Vanderbilt University, had no idea that his work might someday be crucial to deliverance from a global pandemic.
Yet, two coronavirus vaccines are founded on a design developed by Dr. Graham and his colleagues.
The mRNA vaccines developed by Pfizer/BioNTech and Moderna use the discoveries by Dr. Graham and his colleagues and fellow Albany Prize recipients Katalin Karik, Ph.D.and Drew Weissman, M.D., Ph.D., both at the University of Pennsylvania.
The idea of creating a vaccine with messenger RNA, or mRNA, the substance that converts DNA into proteins, goes back decades. However, early efforts to create mRNA vaccines failed because the raw RNA was destroyed before generating the desired response.
Drs. Karik and Weissman came up with the notion that modifying an element of mRNA would enable it to slip past the immune system undetected. Along with important contributions of other scientists, the modifications Dr. Karik and Dr. Weissman discovered allowed mRNA to become a promising delivery system for both vaccines and drugs.
Another key contribution to the mRNA vaccines is thebioengineered protein developed by Dr. Graham and his collaborators. The protein design was based on the observation that so-called fusion proteins, the pieces of the virus that enable it to invade a cell, are shape-shifters, presenting different surfaces to the immune system after the virus fuses with and infects cells. Dr. Graham and his colleagues learned that antibodies against the post-fusion protein are far less effective at stopping an infection.
Dr. Grahams lab at the National Institutes of Health (NIH) started working with Moderna in 2017 to design a rapid manufacturing system for vaccines. In January 2019, they were preparing a demonstration project, a clinical trial to test whether Dr. Grahams protein design and Modernas mRNA platform could be used to create a vaccine against Nipah, a deadly virus spread by bats in Asia.
Their plans changed rapidly when they learned on January 7, 2020, that a coronavirus was causing the epidemic of respiratory disease in China.
We agreed immediately that the demonstration project would focus on this new virus instead of Nipah, Dr. Graham said. Moderna produced a vaccine within six weeks. The first patient was vaccinated in an NIH-led clinical study on March 16, 2020. The early results from Modernas 30,000-volunteer, late-stage trial showed it was nearly 95 percent effective at preventing Covid-19.
Dr. Graham is confident that carefully designed vaccines using nucleic acids reflect the future of new vaccines. Already, two major drug companies are doing advanced clinical trials for RSV vaccines based on the designs we discovered, he said.
In a larger sense, the pandemic may become the event that paves the way for better, possibly less expensive, and more plentiful vaccines.
Basic research informs everything we do, and planning and preparedness can make such a difference in how we get ahead of these epidemics, Dr. Graham said.
During his career, Dr. Grahams primary interests were viral pathogenesis, immunity, and vaccine development. Despite his retirement, his laboratory will remain focused on respiratory viral pathogens, pandemic preparedness, and emerging viral diseases. He applied structural biology, protein engineering, and other new technologies to create vaccines for unmet needs and emerging threats, advancing the principles of precision vaccinology. He was involved in the clinical evaluation of candidate vaccines for more than 30 years and has an ongoing interest in science education and expanding research opportunities for underrepresented minorities. He has led the development and testing of new vaccines for many global pathogens, including RSV, influenza, HIV, Ebola, West Nile, chikungunya, Zika, SARS, and MERS.
It is a great honor to be associated with Dr. Karik and Dr. Weissman and a privilege to be among previous Albany Prize recipients, said Dr. Graham. I am very grateful to all those who have helped me on my journey and to my early mentors for their generosity and inspiration.
PioneeringMessenger RNA Research
When she was in graduate school in the 1970s,Katalin Karik, Ph.D., learned about something that would become a career-defining obsession: Messenger RNA (mRNA).
Dr. Karik, a biochemist, believed in its enormous potential, but for decades she relentlessly explored how the single-stranded molecules of genetic code could be used to treat conditions from strokes and cancer to influenza.
In mRNA vaccine technology, synthetic mRNA is placed as a messenger in cells to oversee the appropriate protein production in the human body. It teaches the immune system to protect against new invaders. The idea is not new, but researchers could not use the mRNA without serious side effects.
Researchers began to give up on the technology, but Dr. Karik kept insisting that it could work, enduring a fair share of rejection in the scientific community.
Drs. Karik and Weissman investigated RNA-mediated immune activation, and in groundbreaking research, they discovered that nucleoside modifications suppress the immunogenicity of RNA. With the support of NIH, their team demonstrated the feasibility of using nucleoside-modified mRNA for protein replacement, thus opening a new field of therapy.
The breakthrough came when Dr. Karik and her fellow Albany Prize recipient Drew Weissman, M.D., Ph.D., an immunologist, made a critical discovery at the University of Pennsylvania. To slip synthetic mRNA past the cells defenses, they realized that they had to tweak one of its molecular building blocks, the nucleosides that comprise a strand of RNA. Their novel solution has been described as the biological equivalent of swapping out a tire; essentially, the side effects could be eliminated, opening doors to develop various new vaccines and drugs. The results were published in 2005, and patents were secured.
The founding scientists of BioNTech, established in 2008 in Mainz, Germany, understood the tremendous potential of the Karik-Weissman discovery and hired Dr. Karik in 2013 to oversee its mRNA research.
Using the new technology, BioNTech and Pfizer together developed a coronavirus vaccine. Modernas vaccine is also based on nucleoside-modified mRNA.
Im hopeful, Dr. Karik said, now that there is so much interest and excitement for research, that it will be possible to develop mRNA technology for prevention and treatment of other diseases, too.
No Rest Until the World Has Access to the Vaccine
An international leader in RNA biology, Drew Weissman, M.D., Ph.D., Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, has a sharp focus on providing global vaccine access.
Research by Dr. Weissman and fellow Albany Prize recipient KatalinKarik, Ph.D.,laid one part of the groundwork for the mRNA vaccines for Covid-19 developed by Pfizer/BioNTech and Moderna, enabling the creation and emergency use authorization of these vaccines within nine months. Thus far,more than 370 million dosesof one of these mRNA-based Covid vaccines have been administered in the United States.
Covid-19 will continue to be a problem until at least two-thirds of the global population is vaccinated, Dr. Weissman said, calling for efforts to minimize the inequity that has left large parts of the world without access to doses.
There are two things that have to happen for us to get the pandemic under control and stop the variants from appearing. We have to vaccinate the entire world, and countries need to have a high enough percentage of people vaccinated somewhere between 75-85 percent in order to reach herd immunity. Until that happens, variants will keep appearing, he said.
Dr. Weissmans lab is working on multiple projects to help make vaccines more accessible. My lab and I personally have a big issue with equality of vaccine access. We are working with the government of Thailand to build its own vaccine. The country isnt content to wait in line to buy vaccines from another country. They will soon be able to make a Covid-19 vaccine in Thailand and supply it to several surrounding low- and middle-income countries. I am also working with World Health Organization to provide similar access in Africa, he said.
Currently, Dr. Weissmansresearchfocuses on RNA and innate immune system biology and applying these findings to vaccine research, therapeutics,and gene therapy. His lab is developing many vaccines for pathogens, including malaria, norovirus, influenza, C. difficile, HSV2, HIV, HCV, and vaccines for potential future pandemics, universal influenza, andpancoronavirus. His lab also develops mRNA delivery of proteins, including genetically deficient, therapeutic, and monoclonal antibodies.
Dr. Weissmans lab has recently developed new technologies to deliver mRNA-LNPs to specific cell types with a simple injection. The cells and organs targeted thus far include lung, heart, brain, CD4+ cells, T cells, and bone marrow stem cells.New therapies are being developed to treat genetic and other disorders for diseases, such as sickle cell anemia.
The Albany Medical Center Prize in Medicine and Biomedical Research, celebrating its 20th anniversary, was established in 2000 by the late Morris Marty Silverman, a New York City businessman and philanthropist raised in Troy, N.Y., to honor scientists whose work has demonstrated significant outcomes that offer medical value of national or international importance. A $50 million gift commitment from the Marty and Dorothy Silverman Foundation provides for the prize to be awarded annually for 100 years.
Three previous Nobel Prize winners have been among the ranks of researchers honored, and eight Albany Prize recipients have gone on to win the Nobel Prize, including James P. Allison, Ph.D., for his development of immune checkpoint blockade to treat cancer; Shinya Yamanaka, M.D., Ph.D., a leading stem cell scientist; Elizabeth Blackburn, Ph.D., who discovered the molecular nature of telomeres; Bruce Beutler, M.D., and the late Ralph Steinman, M.D., for their discoveries regarding the detailed workings of the immune system; Robert Lefkowitz, M.D., for his work on cell receptors; and Emmanuelle Charpentier, Ph.D., and Jennifer Doudna, Ph.D., for development of a method of genome editing.
For biographies and downloadable photos of the 2021 recipients and more information on The Albany Medical Center Prize in Medicine and Biomedical Research, visit: http://www.amc.edu/TheAlbanyPrize
Sue Ford Rajchel
(518) 262 - 3421
Read the rest here:
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Northwesterns SPORE has made advances in understanding the genetic basis of glioblastoma - News-Medical.Net - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- At the crossroads of reproductive and regenerative medicine: new opportunities for preserving and restoring fertility - ESHRE - September 25th, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021